Health Economics›Uveal melanoma›Metastatic or unresectable disease untreated

Metastatic or unresectable disease untreated

Uveal melanoma · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ipilimumab monotherapy Variant #01	—	R 786 153	84d	—	16.9 mo	2	R 1 572 306 PFS proxy	1
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	—	16.9 mo	2	R 573 911 PFS proxy	1
Ipilimumab and Nivolumab Variant #01 Partial	—	R 78 615	42d	~11.5 mo	~71.9 mo	~4	~R 314 461 PFS proxy · indirect	7
Dacarbazine monotherapy Variant #01	—	R 2 608	21d	1.8 mo	16.9 mo	2	R 5 217 PFS proxy	2
Melphalan isolated hepatic perfusion Variant #01 Partial	—	—	56d	7.4 mo	—	6	—	1
Tebentafusp monotherapy Variant #01 Partial	—	—	7d	—	21.6 mo	2	—	1

6 of 6 regimens shown